CAR T-Cell Therapy A Turkiyya

SABODA-T far wani sabon nau'i ne na maganin ciwon daji wanda ke amfani da tsarin rigakafi don kawar da kwayoyin cutar kansa. Inda sauran hanyoyin kwantar da hankali suka gaza, lokaci-lokaci yakan iya warkar da marasa lafiya. Wannan blog ɗin zai haskaka duk abin da kuke buƙatar sani game da wannan hanya. Ci gaba da karantawa don ƙarin sani!

Menene Maganin Kwayoyin CAR-T?

Irin wannan jiyya ya ƙunshi gyaggyarawa ƙwayoyin T na majiyyaci, nau'in ƙwayoyin rigakafi, a cikin dakin gwaje-gwaje don su ɗaure su kashe ƙwayoyin cutar kansa. Wani bututu yana jigilar jini daga wata jijiya a hannun majiyyaci zuwa na'urar apheresis (ba a nuna ba), wacce ke fitar da fararen jini, gami da ƙwayoyin T, kuma ta mayar da sauran jinin ga majiyyaci. 

Sa'an nan kuma ana gyare-gyaren kwayoyin halittar T sel a cikin dakin gwaje-gwaje don ƙunsar kwayar halitta don mai karɓa na musamman wanda aka sani da mai karɓar antigen na chimeric (CAR). Kwayoyin CAR T suna ninka a cikin dakin gwaje-gwaje kafin a shigar da su cikin majiyyaci da yawa. Kwayoyin CAR T za su iya gane antigen da ke kan sel masu ciwon daji, wanda ke kashe kwayoyin cutar kansa.

Menene hanya don CAR-T Cell far?

Tsarin jiyya na CAR-T, wanda ke ɗaukar makonni kaɗan, ya ƙunshi matakai da yawa:

Ana fitar da ƙwayoyin T daga jinin ku ta amfani da bututu da aka sanya cikin jijiya ta hannu. Wannan yana ɗaukar sa'o'i biyu.

Kwayoyin T ana jigilar su zuwa wani wuri inda suke yin gyare-gyaren kwayoyin halitta don zama ƙwayoyin CAR-T. Makonni biyu zuwa uku sun wuce duk wannan.

Ana sake dawo da ƙwayoyin CAR-T cikin jinin ku ta ɗigo. Wannan yana buƙatar sa'o'i da yawa.

Kwayoyin CAR-T sun yi niyya kuma suna kawar da kwayoyin cutar kansa a cikin jiki. Bayan karbar maganin CAR-T, za a sa ido sosai.

Menene illolin maganin CAR-T?

Ciwon saki na cytokine, ko CRS, shine sakamako na gefen CAR T-cell. Wani suna don ita shine "guguwar cytokine." Yana da kusan 70-90% na marasa lafiya, amma yana ɗaukar kwanaki biyar zuwa bakwai kawai. Yawancin mutane suna kwatanta shi da kamuwa da mugun kamuwa da mura, cike da zazzabi mai zafi, gajiya, da ciwon jiki. 

Kwanaki na biyu ko na uku bayan jiko shine yawanci lokacin da ya fara. Yana faruwa ne saboda tsarin garkuwar jiki da ke mayar da martani ga yaɗuwar ƙwayoyin T da kuma kai hari kan m.

CRES, wanda ke tsaye ga CAR T-cell-related encephalopathy syndrome, shine sauran mummunan tasiri. Kusan kwana biyar bayan jiko, yawanci yana farawa. Marasa lafiya na iya samun rudani da ruɗewa, kuma a wasu lokatai suna iya kasa yin magana na kwanaki da yawa. 

Ko da yake CRES na iya jujjuyawa kuma yawanci yana ɗaukar kwanaki biyu zuwa huɗu, yana iya zama damuwa ga marasa lafiya da danginsu. Duk ayyukan jijiyoyi a hankali suna komawa al'ada a cikin marasa lafiya.

Wane nau'in ƙwayoyin kansa ne za a iya bi da su tare da CAR-T Cell Therapy? 

Only patients with adult B-cell non-lymphoma Hodgkin’s or pediatric acute lymphoblastic leukemia who have already tried two unsuccessful conventional therapies can currently use CAR T-cell therapy products that have received FDA approval. However, CAR T-cell therapy is now being tested in clinical studies as a first or second-line treatment for adult lymphoma and pediatric acute lymphoblastic leukemia.

Menene fa'idodin maganin CAR-T?

Babban fa'idar ita ce maganin CAR T-cell yana buƙatar jiko ɗaya kawai kuma galibi yana buƙatar makonni biyu na kulawar marasa lafiya. Marasa lafiya da lymphoma ba Hodgkin da cutar sankarar yara da aka gano kwanan nan, a gefe guda, yawanci suna buƙatar chemotherapy na akalla watanni shida ko fiye.

Amfanin maganin CAR T-cell, wanda shine ainihin magani mai rai, na iya dawwama shekaru da yawa. Idan kuma lokacin da sake dawowa ya faru, ƙwayoyin za su iya ganowa da kuma kai hari ga ƙwayoyin cutar kansa saboda suna iya rayuwa a cikin jiki na tsawon lokaci. 

Kodayake bayanin yana ci gaba, kashi 42 cikin 19 na marasa lafiya na lymphoma manya waɗanda suka yi amfani da CD15 CAR T-cell magani har yanzu suna cikin gafara bayan watanni XNUMX. Kuma bayan watanni shida, kashi biyu bisa uku na marasa lafiya da ke fama da cutar sankarar mahaifa mai tsanani na lymphoblastic na yara har yanzu suna cikin gafara. Abin takaici, waɗannan majiyyatan suna da ciwace-ciwacen ciwace-ciwacen daji waɗanda ba a samu nasarar yi musu magani ta amfani da ƙa'idodin kulawa na gargajiya ba.

Wane nau'in marasa lafiya ne za su zama masu karɓa na CAR-T Cell Therapy?

Mafi kyawun ɗan takarar don CAR T-cell far a wannan lokacin shine ƙaramin yaro tare da cutar sankarar lymphoblastic mai tsanani ko kuma balagagge tare da lymphoma mai tsanani na B-cell wanda ya riga ya sami layi biyu na rashin tasiri. 

Kafin ƙarshen 2017, babu wani tsarin kulawa da aka yarda da shi ga marasa lafiya waɗanda suka riga sun shiga cikin layi biyu na jiyya ba tare da samun gafara ba. Magani kawai da FDA ta amince da shi wanda ya zuwa yanzu ya tabbatar da cewa yana da fa'ida sosai ga waɗannan marasa lafiya shine CAR T-cell far.

Menene iyakokin CAR-T Cell therapy a Turkiyya?

A pilot gwajin gwaji (NCT04206943) designed to assess the safety and feasibility of ISIKOK-19 T-cell therapy in patients with relapsed and refractory CD19+ tumors was conducted and participating patients received ISIKOK-19 infusions between October 2019 and July 2021. Production data of the first 8 patients and the clinical outcome of 7 patients who received ISIKOK-19 cell infusion is presented in this study.

results: An shigar da marasa lafiya tara don gwaji (ALL n = 5 da NHL n = 4) amma marasa lafiya 7 kawai zasu iya samun magani. Biyu daga cikin ukun DUKAN marasa lafiya da uku daga cikin marasa lafiya na NHL huɗu sun sami cikakkiyar amsa / juzu'i (ORR 72%). Marasa lafiya hudu (57%) suna da abubuwan da suka shafi CAR-T (CRS, CRES, da pancytopenia). Marasa lafiya biyu ba su da amsa kuma suna da cutar ci gaba bayan maganin CAR-T. Marasa lafiya guda biyu da ke da wani bangare na amsawa suna da cutar ci gaba a lokacin
bi-bi.

Kammalawa: Ingancin samarwa da cika ka'idojin kula da ingancin sun kasance masu gamsarwa don samar da ilimi. Adadin amsawa da bayanan martaba an yarda da su ga wannan rukunin mara lafiya da aka riga aka riga aka gyara/masu hanawa. Kwayoyin ISIKOK-19 sun bayyana a matsayin amintaccen, tattalin arziki, da ingantaccen zaɓi na magani don ciwace-ciwacen CD19. Abubuwan da aka samu na wannan binciken suna buƙatar zama
goyan bayan gwajin gwaji na asibiti na yanzu na ISIKOK-19.

Don ƙare

Wannan yana wakiltar ci gaba mai mahimmanci a cikin kula da cutar sankarar bargo da B-cell lymphoma. Bugu da ƙari, yana ba da bege ga waɗanda aka yi hasashen rayuwarsu za ta wuce watanni shida kacal. Yanzu da muka gano hanyoyin juriya kuma mun ƙirƙiri ƙarin dabaru don yaƙar su, nan gaba yana da alama ya fi dacewa.

Don ƙarin cikakkun bayanai kan CAR-T Cell Therapy a Turkiyya, je zuwa mu yanar. Tuntuɓi ƙwararrun ƙwararrun masu ba da kiwon lafiya anan a CancerFax don shawarwari na kyauta don aiwatar da tsarin kulawa da ya dace don buƙatun lafiyar ku!

Hoto: Daya daga cikin asibiti a Turkiyya inda aka gudanar da gwajin jinya na CAR T.